Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure [0.03%]
先前接受过IL-17抑制剂治疗失败的银屑病患者接受Bimekizumab治疗后的疗效
Eingun James Song,Prieuer Pretorius,Diego Ruiz Dasilva et al.
Eingun James Song et al.
Despite advancements in psoriasis therapeutics, biologic discontinuation and switching still happen frequently, with the most common reasons being lack of efficacy or treatment intolerance. Conventional teaching has been to switch out of th...
Psoriatic Arthritis Characteristics and Comorbidities in North Africa: Results of a Multicenter Retrospective Study [0.03%]
北非银屑病关节炎的临床特点及相关疾病：一项多中心回顾性研究的结果
Abderrahim Majjad,Sofia El Guarti,Hamza Mansouri et al.
Abderrahim Majjad et al.
Background: Psoriatic arthritis (PsA) exhibits heterogeneity across different populations. Given the limited research on PsA in Africa, this study aims to characterize disease features and various cardiovascular disease r...
Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study [0.03%]
关于泛发性脓疱型银屑病的诊断、治疗和负担的患者体验：一项国际在线调查与定性访谈研究
Mark Lebwohl,Hideki Fujita,Kilian Eyerich et al.
Mark Lebwohl et al.
Background: Generalized pustular psoriasis (GPP) is a rare, serious, chronic, neutrophilic skin disease, distinct from plaque psoriasis, characterized by recurrent flares of cutaneous erythema and widespread sterile pustu...
Characteristics and Contributing Factors for Difficult to Treat Psoriatic Arthritis- a Comparative Analysis [0.03%]
难治性银屑病关节炎的特征及影响因素-对比研究
Ong Ping Seung,Lee Pei Jia
Ong Ping Seung
Objective: To assess the contributing factors and clinical characteristics of difficult-to-treat (D2T) psoriatic arthritis (PsA). Patients and methods: ...
Real-world Evidence of Brodalumab Safety for the Treatment of Psoriasis [0.03%]
布罗利单抗治疗银屑病的真实世界安全性研究
Mark Lebwohl,Eingun James Song,Tina Bhutani et al.
Mark Lebwohl et al.
Plaque psoriasis is a chronic skin disorder involving dysregulated inflammation. While numerous biologic therapies targeting inflammatory mediators have been approved for moderate-to-severe psoriasis, their safety profiles may include an in...
Clinical Considerations for the Use of Biologic Agents in Psoriasis Patients With a History of Lymphoma [0.03%]
淋巴瘤病史的银屑病患者使用生物制剂的临床考虑因素
Allison Bai,Emily Gartrell,Olivia Whittaker et al.
Allison Bai et al.
Background: Managing psoriasis in patients with a history of lymphoma presents a unique clinical challenge. Psoriasis is associated with significant comorbidities such as cardiovascular disease and inflammatory arthritis, making optimal tre...
The Role of Pharmacy Benefit Managers in Access to Biologics for Dermatologic Conditions [0.03%]
生物制剂治疗皮肤病 доступ性问题中的药品福利管理者的角色
Melissa C Leeolou,Justin L Jia,Jason Harris et al.
Melissa C Leeolou et al.
In this commentary, we discuss the role of pharmacy benefit managers (PBMs) on access to biologics for patients with psoriasis. We highlight structural and system level barriers to biologics access, as well as how PBMs work as intermediarie...
Letter to the Editor Regarding "Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study" [0.03%]
有关「关于银屑病关节炎的 Ixekizumab 疗效持续性和治疗持久性的预测因素：意大利多中心研究结果」一文的读者来信
Joaquín Borras-Blasco,Alejandro Valcuende-Rosique,Silvia Cornejo-Uixeda
Joaquín Borras-Blasco
A Trial of Coach-Supported, Smartphone-Delivered Cognitive Behavioral Therapy for Psoriasis With Comorbid Depression [0.03%]
一项针对银屑病伴抑郁的智能手机递送的认知行为疗法辅助教练支持试验
John S Barbieri,Megan H Noe,Nora Bensellam et al.
John S Barbieri et al.
Background: Psoriasis is associated with increased risk of depression. Although cognitive behavioral therapy (CBT) is an evidence-based treatment, access remains limited. ...
Melissa C Leeolou,Justin L Jia,Dayna L Pham et al.
Melissa C Leeolou et al.